Tislelizumab Plus Chemotherapy As First-Line Treatment of Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer (final Analysis of RATIONALE-304: a Randomized Phase III Trial)
ESMO OPEN（2024）
Key words
anti-PD-1 antibody,non-small-cell lung cancer,fi rst line,stage IIIB-IV,tislelizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined